We are live on
!
Find out more
Rafferty Asset Management Portfolio holdings
AUM
$24.6B
1-Year Est. Return
47.06%
This Fund
S&P 500
This Quarter
Est. Return
+8.79%
1 Year Est. Return
+47.06%
3 Year Est. Return
+108.18%
5 Year Est. Return
+135.84%
10 Year Est. Return
+427.13%
AUM
$17.7B
AUM Growth
+$2.98B
(+20%)
Cap. Flow
+$1.81B
Cap. Flow
% of AUM
10.19%
Top 10 Holdings %
Top 10 Hldgs %
35.18%
Holding
1,173
New
33
Increased
727
Reduced
328
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$505M |
| 2 |
Intel
INTC
|
+$122M |
| 3 |
Apple
AAPL
|
+$122M |
| 4 |
Microsoft
MSFT
|
+$98.1M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$97.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$90.1M |
| 2 |
VanEck Gold Miners ETF
GDX
|
+$37.3M |
| 3 |
iShares MSCI Brazil ETF
EWZ
|
+$32.8M |
| 4 |
State Street SPDR Bloomberg High Yield Bond ETF
JNK
|
+$15.9M |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$15.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 45.79% |
| 2 | Financials | 10.21% |
| 3 | Healthcare | 7.68% |
| 4 | Consumer Discretionary | 4.29% |
| 5 | Energy | 4.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Neurocrine Biosciences
NBIX
$18.7B
| $8.4M | 0.05% |
89,031
+18,043
| +25% | +$1.76M |
|
252
Arrowhead Research
ARWR
$12.3B
| $8.39M | 0.05% |
235,213
-27,218
| -10% | -$938K |
|
253
Ionis Pharmaceuticals
IONS
$8.81B
| $8.39M | 0.05% |
204,388
+501
| +0.2% | +$19.3K |
|
254
Natera
NTRA
$38.6B
| $8.36M | 0.05% |
171,717
+45,969
| +37% | +$2.35M |
|
255
Alkermes
ALKS
$8.39B
| $8.35M | 0.05% |
266,792
+11,124
| +4% | +$337K |
|
256
Oneok
OKE
$56.1B
| $8.35M | 0.05% |
135,213
+688
| +0.5% | +$42.6K |
|
257
Alnylam Pharmaceuticals
ALNY
$27.4B
| $8.27M | 0.05% |
43,553
+5,362
| +14% | +$1.06M |
|
258
Exelixis
EXEL
$14.1B
| $8.27M | 0.05% |
432,717
+24,879
| +6% | +$480K |
|
259
Novavax
NVAX
$1.22B
| $8.26M | 0.05% |
1,112,073
+68,796
| +7% | +$541K |
|
260
CRISPR Therapeutics
CRSP
$4.77B
| $8.25M | 0.05% |
146,909
-10,537
| -7% | -$598K |
|
261
Beam Therapeutics
BEAM
$2.73B
| $8.24M | 0.05% |
257,991
+46,323
| +22% | +$1.5M |
|
262
SiriusXM
SIRI
$10.4B
| $8.21M | 0.05% |
181,201
+38,065
| +27% | +$1.44M |
|
263
Vaxcyte
PCVX
$8.08B
| $8.21M | 0.05% |
164,309
-15,572
| -9% | -$738K |
|
264
State Street
STT
$50.2B
| $8.18M | 0.05% |
111,778
-10,674
| -9% | -$767K |
|
265
Prothena Corp
PRTA
$440M
| $8.16M | 0.05% |
119,578
-22,111
| -16% | -$1.43M |
|
|
FOLD
266
DELISTED
Amicus Therapeutics
FOLD
| $8.15M | 0.05% |
648,512
+53,811
| +9% | +$639K |
|
|
FLG
267
Flagstar Bank National Association
FLG
$5.94B
| $8.14M | 0.05% |
241,400
-121,059
| -33% | -$3.67M |
|
268
General Dynamics
GD
$103B
| $8.1M | 0.05% |
37,654
-1,220
| -3% | -$263K |
|
|
WBA
269
DELISTED
Walgreens Boots Alliance
WBA
| $8.1M | 0.05% |
284,148
+68,900
| +32% | +$2.24M |
|
270
TJX Companies
TJX
$176B
| $8.09M | 0.05% |
95,459
+13,019
| +16% | +$1.03M |
|
271
Acadia Pharmaceuticals
ACAD
$4.55B
| $8.05M | 0.05% |
336,029
+3,668
| +1% | +$81.5K |
|
272
Zoetis
ZTS
$31.9B
| $8.05M | 0.05% |
46,730
+3,405
| +8% | +$589K |
|
273
Willis Towers Watson
WTW
$31.7B
| $8.04M | 0.05% |
34,145
-1,850
| -5% | -$426K |
|
274
Cigna
CI
$76.1B
| $8.03M | 0.05% |
28,612
+1,873
| +7% | +$488K |
|
275
Bank OZK
OZK
$5.57B
| $8.02M | 0.05% |
199,699
+75,053
| +60% | +$2.69M |
|
Similar funds
CS
AF
SC
JG
Rafferty Asset Management's Q2 2023 Portfolio in Review
As of Q2 2023, Rafferty Asset Management held 1,173 positions worth $17.7B, up 20% from $14.8B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Rafferty Asset Management deployed $1.81B of net new capital in Q2 2023, opening 33 new positions and adding to 727 existing holdings. Its largest new stake was Biomea Fusion: 136,903 shares worth $3.01M.
By sector, the portfolio is most concentrated in Technology at 46% of assets, up from 42% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was NVIDIA, an estimated $90.1M trimmed.
- Rafferty Asset Management's largest Q2 2023 buy was Biomea Fusion: 136,903 shares worth $3.01M.
- Rafferty Asset Management added most to iShares 20+ Year Treasury Bond ETF in Q2 2023, an estimated $505M increase.
- Rafferty Asset Management's biggest Q2 2023 reduction was NVIDIA, cutting an estimated $90.1M.
- Rafferty Asset Management fully exited Prometheus Biosciences, Inc. Common Stock in Q2 2023, selling an estimated $6.38M.
- Rafferty Asset Management's ten largest holdings make up 35% of its $17.7B portfolio in Q2 2023.
- Rafferty Asset Management opened 33 new positions and closed 84 in Q2 2023.
- Rafferty Asset Management's portfolio value rose 20% quarter-over-quarter to $17.7B.
Based on Rafferty Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.